The Global Glaucoma Surgery Devices Market surged to US$ 1.1 billion in 2022 and is poised for substantial growth, projected to reach US$ 6.0 billion by 2031. The market is expected to exhibit a remarkable Compound Annual Growth Rate (CAGR) of 24.2% during the forecast period from 2024 to 2031.
Glaucoma surgery devices primarily target the reduction of intraocular pressure (IOP), a pivotal modifiable risk factor in glaucoma management. By effectively lowering IOP, these devices play a crucial role in halting or mitigating the progression of the disease, thereby preventing further damage to the optic nerve. Consequently, the primary goal of glaucoma therapy is to alleviate intraocular pressure.
The exponential growth of the glaucoma surgery devices market can be attributed to several key factors. Firstly, there is a notable increase in the prevalence of glaucoma cases globally, compounded by the rising geriatric population, which is particularly vulnerable to ocular diseases. Additionally, there is a growing demand for minimally invasive glaucoma surgery (MIGS) procedures, driven by their effectiveness and patient preference.
Furthermore, continuous technological advancements in glaucoma surgery devices are expected to further fuel market growth, catering to the evolving needs of patients and healthcare providers alike.
-
Punches
-
USC Marker
-
USC Planer
-
USC Shaver
-
Ophthalmic Clinics
-
Hospitals
Major players are Ziemer Ophthalmic Systems AG, Corza Medical, Alcon, Inami & Co Ltd, Katalyst Surgical, Lumenis, Millennium Surgical, Moria Surgical, Zabbys and Allergan.
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian